Ketorolac injection represents a powerful option for managing moderate to severe pain in adult patients when oral administration is not feasible. As a nonsteroidal anti-inflammatory drug (NSAID) of the pyrrolizine acetic acid class, it provides effective analgesia primarily through the inhibition of cyclooxygenase (COX) enzymes. This mechanism reduces the production of prostaglandins, which are key mediators of pain, fever, and inflammation. Understanding the precise dosing protocols, potential risks, and clinical considerations is essential for healthcare professionals to utilize this medication safely and effectively.
Standard Adult Dosing Regimens
The initial adult dose of ketorolac injection is typically 30 mg administered intramuscularly or intravenously. For ongoing pain management, subsequent doses of 15 to 30 mg may be given every 4 to 6 hours as needed. It is crucial to note that the total daily dosage must not exceed 120 mg, and the duration of therapy is strictly limited to a maximum of 5 days. This limitation exists due to the increased risk of serious adverse effects associated with prolonged NSAID use.
Adjusted Dosing for Specific Populations
For elderly patients aged 65 years and older, initiating therapy with a reduced dose of 15 mg is strongly recommended. This adjustment accounts for age-related physiological changes and a higher prevalence of comorbidities that can increase susceptibility to adverse reactions. Similarly, individuals with moderate to severe renal impairment, defined as a creatinine clearance between 30 and 50 mL/min, should also begin treatment at the 15 mg dose. Patients with mild to moderate hepatic impairment may require a dose reduction, and ketorolac is contraindicated in those with severe liver disease.
Routes of Administration and Onset
Ketorolac injection can be delivered via two primary parenteral routes: intramuscular (IM) and intravenous (IV). While both methods are effective, the IV route generally produces a faster onset of analgesic action, making it preferable in acute, severe pain scenarios where rapid relief is critical. The IM injection, however, remains a reliable and widely used option. The bioavailability of the drug is complete regardless of the route, as the medication is administered directly into the systemic circulation rather than through the gastrointestinal tract.
Critical Safety Considerations and Contraindications
The use of ketorolac injection is accompanied by significant safety warnings that mandate careful patient selection. The drug is contraindicated in patients with active peptic ulcer disease, bleeding disorders, severe renal failure, or hypersensitivity to NSAIDs. It should be used with extreme caution in individuals with cardiovascular disease, hypertension, or asthma. Close monitoring for signs of gastrointestinal bleeding, renal dysfunction, and allergic reactions is mandatory throughout the treatment period.
Drug Interactions to Monitor
Clinicians must be vigilant regarding potential drug interactions when prescribing ketorolac. Concurrent use with other NSAIDs, including aspirin, corticosteroids, or anticoagulants like warfarin, significantly elevates the risk of bleeding complications. The combination with angiotensin-converting enzyme (ACE) inhibitors or diuretics may diminish the antihypertensive effect and worsen renal function. Ketorolac can also interfere with the cardioprotective effects of beta-blockers, necessitating careful assessment of the patient's current medication list.
Common and Serious Adverse Effects
While effective, ketorolac injection is associated with a range of side effects, the most common being nausea, heartburn, dizziness, and headache. These symptoms are generally mild but warrant attention if they persist or worsen. More seriously, the drug carries a black box warning regarding the risk of serious cardiovascular thrombotic events, such as myocardial infarction and stroke. This risk appears to increase with the duration of treatment and appears in patients without pre-existing cardiovascular risk factors.
